AIDS MALIGNANCY CONSORTIUM

本申请是由Joseph A.Sparano博士代表Montefiore医疗中心(包括摩西科和韦勒科)和其他四个机构组成的财团提交的，这些机构包括雅各比医疗中心、中北部布朗克斯医院、布朗克斯黎巴嫩医院和长岛犹太人医疗中心。在过去的8年里，仅在蒙特菲奥里医学中心，就有111名与艾滋病毒相关的恶性肿瘤患者在斯帕拉诺·S博士的指导下进行了临床试验。该联盟的六家医院中有五家为布朗克斯区提供服务，该社区的艾滋病毒感染率在全国名列前茅。在布朗克斯的120万居民中，估计约有30,000人在知情(16,000人)或不知情(14,000人)的情况下感染了艾滋病毒。这个社区不仅有以医院为基础的艾滋病毒专门护理诊所，而且有30多个附属于MMC或布朗克斯黎巴嫩医院(BLH)的社区诊所。BLH也有一个积极的社区外展计划。大约有5900名患者接受联盟机构提供的初级艾滋病毒护理。此外，在财团机构中，估计每年新诊断出约110例艾滋病毒相关和艾滋病相关癌症患者，其中46例为系统性淋巴瘤，14例为原发中枢神经系统淋巴瘤，50例为卡波西·S肉瘤。MMC在癌症和艾滋病研究的临床试验方面拥有丰富的经验。它是阿尔伯特·爱因斯坦医学院(AECOM)的大学医院，也是NCI指定的AECOM综合癌症中心的临床分支机构。每年有100多个临床方案有效，400多名患者参加临床试验，参加临床试验的人中约55%要么是非洲裔美国人，要么是拉丁裔。MMC也是东方合作肿瘤学小组的成员。1997年，在ECOG S对MMC S临床试验业绩和数据管理的最后一次审计中，MMC被ECOG评为优秀到杰出。纽约州指定的艾滋病中心设在MMC和BLH，MMC、BLH和Jacobi医学中心参加CPCRA。因此，MMC及其合作伙伴非常适合成为AMC的生产性成员，因为其庞大的患者基础、在癌症临床试验方面的丰富经验以及其首席研究员所展示的科学领导地位。

This application for membership in the AIDS Malignancy Consortium is submitted by Dr. Joseph A. Sparano on behalf of Montefiore Medical Center (including the Moses Division and Weiler Division) and a consortium of four other institutions, including Jacobi Medical Center, North Central Bronx Hospital, Bronx Lebanon Hospital, and Long Island Jewish Medical Center. At Montefiore Medical Center (MMC) alone, 111 patients with HIV-associated malignancies have been enrolled on clinical trials under Dr. Sparano s direction over the past 8 years. The prevalence of HIV infection in the Bronx, the community served by five of the six hospitals in this consortium, is among the highest in the nation. Of the 1.2 million residents of the Bronx, it is estimated that about 30,000 are knowingly (16,000) or unknowingly (14,000) HIV- infected. This community is served not only by hospital-based HIV specialty care clinics, but also by over 30 community-based clinics affiliated with MMC or Bronx Lebanon Hospital (BLH). BLH also has an active community outreach program. Approximately 5900 patients receive primary HIV care by the consortium institutions. Moreover, among consortium institutions, it is estimated that each year there are approximately 110 patients newly diagnosed with HIV-associated and AIDS-associated cancers each year, including 46 patients wit systemic lymphoma, 14 patients with primary CNS lymphoma, and 50 patients with Kaposi s sarcoma. MMC has extensive experience in clinical trials in cancer and AIDS research. It is the University Hospital of the Albert Einstein College of Medicine (AECOM), and as such is the clinical arm of the NCI-designated Comprehensive Cancer Center at AECOM. Each year, over 100 clinical protocols are active, over 400 patients are enrolled on clinical trials, and about 55 percent of those enrolled on clinical trials are either African- American or Latino. MMC is also a member of the Eastern Cooperative Oncology Group. At ECOG s last audit of MMC s clinical trials performance and data management in 1997, MMC was rated as excellent to outstanding by ECOG. New York State- designated AIDS centers are based at MMC and BLH, and MMC, BLH, and Jacobi Medical Center participate in the CPCRA. MMC and its partners are therefore ideally suited to become productive members of AMC because of its large patient base, its considerable experience in cancer clinical trials, and the scientific leadership that has been demonstrated by its principal investigator.